OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical teams navigate the complex drug development process. The acquisition strengthens OpenAI's push into life sciences research, integrating Orchestra's platform into Rosalind, the company's expanding suite of models and tools for biology and drug discovery.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...
Contact us
Questions, corrections, or ideas? Send us a message here. We aim to reply by email within 24 hours.
Thank you. Your message has been sent. We aim to reply by email within 24 hours.Please enter your email address and a message.We could not send your message. Please try again in a little while.